Expression analysis of mir-17-5p, mir-20a and let-7a microRNAs and their target proteins in CD34+ bone marrow cells of patients with myelodysplastic syndromes

Leukemia Research

Volumn 37, Issue 3, 2013, Pages 251-258

  Vasilatou, Diamantina ^a   Papageorgiou, Sotirios G ^a   Kontsioti, Frieda ^a   Kontos, Christos K ^b,c   Tsiotra, Panayiota ^a   Mpakou, Vassiliki ^a   Pavlou, Maria Angeliki S ^c   Economopoulou, Christina ^a   Dimitriadis, George ^a   Dervenoulas, John ^a   Pappa, Vasiliki ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c INSTITUTE OF BIOLOGY   (Greece)

Author keywords

Let 7a; MDS; MicroRNAs; Mir 17 5p; Mir 20a

Indexed keywords

CYCLIN D1; K RAS PROTEIN; MICRORNA; MICRORNA 17 5P; MICRORNA 20A; MICRORNA LET 7A; MYC PROTEIN; PROTEIN BCL 2; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BONE MARROW CELL; CD34 SELECTION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DOWN REGULATION; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; KARYOTYPE; LOW RISK POPULATION; MALE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; ANTIGENS, CD34; BONE MARROW CELLS; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; MALE; MICRORNAS; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS;

EID: 84872965543     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.11.011     Document Type: Article

References (48)

1. Nimer S.D. Myelodysplastic syndromes. Blood 2008, 111:4841-4851.
2. Davids M.S., Steensma D.P. The molecular pathogenesis of myelodysplastic syndromes. Cancer Biol Ther 2010, 10:309-319.
3. Vasilatou D., Papageorgiou S., Pappa V., Papageorgiou E., Dervenoulas J The role of microRNAs in normal and malignant hematopoiesis. Eur J Haematol 2010, 84:1-16.
4. Saberwal G., Lucas S., Janssen I., Deobhakta A., Hu W.Y., Galili N., et al. Increased levels and activity of E2F1 transcription factor in myelodysplastic bone marrow. Int J Hematol 2004, 80:146-154.
5. O'Donnell K.A., Wentzel E.A., Zeller K.I., Dang C.V., Mendell J.T. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005, 435:839-843.
6. Yu Z., Wang C., Wang M., Li Z., Casimiro M.C., Liu M., et al. A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. J Cell Biol 2008, 182:509-517.
7. Saberwal G., Broderick E., Janssen I., Shetty V., Alvi S., Lisak L., et al. Involvement of cyclin D1 and E2F1 in intramedullary apoptosis in myelodysplastic syndromes. J Hematother Stem Cell Res 2003, 12:443-450.
8. Hirai H., Kobayashi Y., Mano H., Hagiwara K., Maru Y., Omine M., et al. A point mutation at codon 13 of the N-ras oncogene in myelodysplastic syndrome. Nature 1987, 327:430-432.
9. Paquette R.L., Landaw E.M., Pierre R.V., Kahan J., Lubbert M., Lazcano O., et al. N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. Blood 1993, 82:590-599.
10. Neubauer A., Dodge R.K., George S.L., Davey F.R., Silver R.T., Schiffer C.A., et al. Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. Blood 1994, 83:1603-1611.
11. Padua R.A., West R.R. Oncogene mutation and prognosis in the myelodysplastic syndromes. Br J Haematol 2000, 111:873-874.
12. Johnson S.M., Grosshans H., Shingara J., Byrom M., Jarvis R., Cheng A., et al. RAS is regulated by the let-7 microRNA family. Cell 2005, 120:635-647.
13. He X.Y., Chen J.X., Zhang Z., Li C.L., Peng Q.L., Peng H.M. The let-7a microRNA protects from growth of lung carcinoma by suppression of k-Ras and c-Myc in nude mice. J Cancer Res Clin Oncol 2010, 136:1023-1028.
14. Esquela-Kerscher A., Trang P., Wiggins J.F., Patrawala L., Cheng A., Ford L., et al. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 2008, 7:759-764.
15. Kurotaki H., Tsushima Y., Nagai K., Yagihashi S. Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia. Acta Haematol 2000, 102:115-123.
16. Giulietti A., Overbergh L., Valckx D., Decallonne B., Bouillon R., Mathieu C. An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods 2001, 25:386-401.
17. Camp R.L., Dolled-Filhart M., Rimm D.L. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004, 10:7252-7259.
18. Rhyasen G.W., Starczynowski D.T. Deregulation of microRNAs in myelodysplastic syndrome. Leukemia 2011, 26:13-22.
19. Erdogan B., Facey C., Qualtieri J., Tedesco J., Rinker E., Isett R.B., et al. Diagnostic microRNAs in myelodysplastic syndrome. Exp Hematol 2011, 39:915-926.e2.
20. Hussein K., Theophile K., Busche G., Schlegelberger B., Gohring G., Kreipe H., et al. Aberrant microRNA expression pattern in myelodysplastic bone marrow cells. Leuk Res 2010, 34:1169-1174.
21. Pons A., Nomdedeu B., Navarro A., Gaya A., Gel B., Diaz T., et al. Hematopoiesis-related microRNA expression in myelodysplastic syndromes. Leuk Lymphoma 2009, 50:1854-1859.
22. Sokol L., Caceres G., Volinia S., Alder H., Nuovo G.J., Liu C.G., et al. Identification of a risk dependent microRNA expression signature in myelodysplastic syndromes. Br J Haematol 2011, 153:24-32.
23. Dostalova Merkerova M., Krejcik Z., Votavova H., Belickova M., Vasikova A., Cermak J. Distinctive microRNA expression profiles in CD34+ bone marrow cells from patients with myelodysplastic syndrome. Eur J Hum Genet 2011, 19:313-319.
24. Fontana L., Pelosi E., Greco P., Racanicchi S., Testa U., Liuzzi F., et al. MicroRNAs 17-5p-20a-106a control monocytopoiesis through AML1 targeting and M-CSF receptor upregulation. Nat Cell Biol 2007, 9:775-787.
25. Garzon R., Pichiorri F., Palumbo T., Iuliano R., Cimmino A., Aqeilan R., et al. MicroRNA fingerprints during human megakaryocytopoiesis. Proc Natl Acad Sci USA 2006, 103:5078-5083.
26. Georgantas R.W., Hildreth R., Morisot S., Alder J., Liu C.G., Heimfeld S., et al. CD34+ hematopoietic stem-progenitor cell microRNA expression and function: a circuit diagram of differentiation control. Proc Natl Acad Sci USA 2007, 104:2750-2755.
27. Venturini L., Battmer K., Castoldi M., Schultheis B., Hochhaus A., Muckenthaler M.U., et al. Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. Blood 2007, 109:4399-4405.
28. Li Z., Lu J., Sun M., Mi S., Zhang H., Luo R.T., et al. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci USA 2008, 105:15535-15540.
29. Li Z., Luo R.T., Mi S., Sun M., Chen P., Bao J., et al. Consistent deregulation of gene expression between human and murine MLL rearrangement leukemias. Cancer Res 2009, 69:1109-1116.
30. Wong P., Iwasaki M., Somervaille T.C., Ficara F., Carico C., Arnold C., et al. The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression. Cancer Res 2010, 70:3833-3842.
31. Mundle S.D., Saberwal G. Evolving intricacies and implications of E2F1 regulation. Faseb J 2003, 17:569-574.
32. Putzer B.M. E2F1 death pathways as targets for cancer therapy. J Cell Mol Med 2007, 11:239-251.
33. Hiebert S.W., Packham G., Strom D.K., Haffner R., Oren M., Zambetti G., et al. E2F-1:DP-1 induces p53 and overrides survival factors to trigger apoptosis. Mol Cell Biol 1995, 15:6864-6874.
34. Holmberg C., Helin K., Sehested M., Karlstrom O. E2F-1-induced p53-independent apoptosis in transgenic mice. Oncogene 1998, 17:143-155.
35. Johnson D.G. The paradox of E2F1: oncogene and tumor suppressor gene. Mol Carcinog 2000, 27:151-157.
36. Hibner U., Coutinho A. Signal antonymy: a mechanism for apoptosis induction. Cell Death Differ 1994, 1:33-37.
37. Shell S., Park S.M., Radjabi A.R., Schickel R., Kistner E.O., Jewell D.A., et al. Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci USA 2007, 104:11400-11405.
38. Akao Y., Nakagawa Y., Naoe T. Let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol Pharm Bull 2006, 29:903-906.
39. Takamizawa J., Konishi H., Yanagisawa K., Tomida S., Osada H., Endoh H., et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004, 64:3753-3756.
40. Zhang H.H., Wang X.J., Li G.X., Yang E., Yang N.M. Detection of let-7a microRNA by real-time PCR in gastric carcinoma. World J Gastroenterol 2007, 13:2883-2888.
41. Jongen-Lavrencic M., Sun S.M., Dijkstra M.K., Valk P.J., Lowenberg B. MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood 2008, 111:5078-5085.
42. Chaussepied M., Ginsberg D. Transcriptional regulation of AKT activation by E2F. Mol Cell 2004, 16:831-837.
43. Hallstrom T.C., Nevins J.R. Specificity in the activation and control of transcription factor E2F-dependent apoptosis. Proc Natl Acad Sci USA 2003, 100:10848-10853.
44. Moon N.S., Di Stefano L., Dyson N. A gradient of epidermal growth factor receptor signaling determines the sensitivity of rbf1 mutant cells to E2F-dependent apoptosis. Mol Cell Biol 2006, 26:7601-7615.
45. Chen L., Li C., Zhang R., Gao X., Qu X., Zhao M., et al. MiR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma. Cancer Lett 2011, 309:62-70.
46. Zuo Z., Calin G.A., de Paula H.M., Medeiros L.J., Fernandez M.H., Shimizu M., et al. Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome. Blood 2011, 118:413-415.
47. Ohshima K., Inoue K., Fujiwara A., Hatakeyama K., Kanto K., Watanabe Y., et al. Let-7 microRNA family is selectively secreted into the extracellular environment via exosomes in a metastatic gastric cancer cell line. PloS ONE 2010, 5:e13247.
48. Pigati L., Yaddanapudi S.C., Iyengar R., Kim D.J., Hearn S.A., Danforth D., et al. Selective release of microRNA species from normal and malignant mammary epithelial cells. PloS ONE 2010, 5:e13515.